Subject: News on Myloral -- Autoimmune Inc.

From: [email-masked] (Michael Watkins)
Date: Mon, 04 Aug 1997 21:13:03 +0100

Autoimmune Inc. reported in a press release today
that they had "encouraging preliminary results 
from magnetic resonance imaging have 
been found for one of the four subsets of patients studied".

The treatment groups were divided into male and female and
HLA type DR2 positive and negative.  It will be interesting
to see which group was promising.  I believe that the
Phase I trial suggested that males who were DR2 negative
would benefit from this therapy, so this may be confirmation.